Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | TACR2 | P21452 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.33 |
| ▸ | CDC25B | P30305 | 7/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.32 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19292382 | 1.00 | PDE2A (0.41) | PDE2ATACR2CA1CA2CA9 | |
| SCHEMBL18787318 | 0.90 | PDE2A (0.48) | PDE2ATACR2CA1CA2CA9 | |
| SCHEMBL20653964 | 0.87 | PDE2A (0.47) | PDE2ATACR2CA1CA2CA9 | |
| SCHEMBL18788241 | 0.85 | PDE2A (0.42) | PDE2ATACR2CA1CA2CA9 | |
| SCHEMBL24160544 | 0.83 | BCHE (0.33) | BCHE | |
| SCHEMBL20404016 | 0.83 | PDE2A (0.40) | PDE2ATACR2CA1CA2CA9 | |
| SCHEMBL19859840 | 0.82 | PDE2A (0.42) | PDE2ATACR2CA1CA2CA9 | |
| SCHEMBL18788255 | 0.78 | TP53 (0.31) | TP53 | |
| SCHEMBL23773180 | 0.78 | PDE2A (0.31) | PDE2A | |
| SCHEMBL18787315 | 0.77 | PDE2A (0.52) | PDE2ACA1CA2CA9HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787832-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-3932931-A1 | A NEBULIZER COMPRISING A PHARMACEUTICAL COMPOSITION COMPRISING 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210253622-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2021-08-19 | — | — | US | disclosed |
| EP-3351552-B1 | 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10941177-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190016749-A1 | 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2019-01-17 | — | — | US | disclosed |
| EP-3351552-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3210993-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170114086-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253622-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, SLC29A1, RNMT | PDE2A 507/4885TACR2 4679/4885CA1 1593/4885 |
| US-20190016749-A1 | 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, SLC29A1, RNMT | PDE2A 507/4885TACR2 4679/4885CA1 1593/4885 |
| US-20170114086-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, SLC29A1, RNMT | PDE2A 507/4885TACR2 4679/4885CA1 1593/4885 |
| US-11787832-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | PNP, RNMT, SLC29A1 | PDE2A 491/4885TACR2 4707/4885CA1 1995/4885 |
| US-10941177-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | PNP, RNMT, SLC29A1 | PDE2A 491/4885TACR2 4707/4885CA1 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.